Lower-Risk Profile Compared to Direct GH Because sermorelin works through the body's own feedback system, the risk of pushing GH or IGF-1 too high is built-in lower than with direct recombinant GH injections
Fajardo, V., Alonso-Aperte, E
The advent of incretin-based therapies and the expansion to multi-receptor agonist peptides targeting glucagon-like peptide 1 (GLP1), glucose-dependent insulinotropic polypeptide (GIP), glucagon, and amylin receptors has transformed obesity treatment, demonstrating average weight loss of more than 20% in humans and improvements in a broad range of obesity-related comorbidities
Cell Mol Life Sci 60 : 620 El-Hamamsy I, Stevens LM, Carrier M, Pellerin M, Bouchard D, Demers P, Cartier R, Page P, Perrault LP 2007 Effect of intravenous N -acetylcysteine on outcomes after coronary artery bypass surgery: a randomized, double-blind, placebo-controlled clinical trial